ACUTE RETINAL NECROSIS AFTER INTRAVITREAL DEXAMETHASONE IMPLANT. A CASE REPORT
Authors:
Z. Šulavíková 1; J. Anwarzai 1; V. Krásnik 2
Authors place of work:
Očná klinika, Fakultná nemocnica Trenčín
1; Klinika oftalmológie LFUK a UNB, Bratislava
2
Published in the journal:
Čes. a slov. Oftal., 78, 2022, No. 3, p. 144-148
Category:
Case Report
doi:
https://doi.org/10.31348/2022/17
Summary
Introduction: Ozurdex® (Allergan Pharmaceuticals, Castlebar Road, Westport, Ireland) is an intravitreal implant containing 0.7 mg of dexamethasone. It is indicated in adult patients for the treatment of diabetic macular edema, cystoid macular edema due to central retinal vein occlusion, and in patients with non-infectious uveitis. Common complications after Ozurdex® administration include an increase in intraocular pressure, cataract progression or conjunctival suffusion. Acute retinal necrosis after Ozurdex® administration is a very rare and serious complication. According to our current research, this is the fourth published case. Extreme caution must be exercised when treating immunosuppressed patients with Ozurdex®.
Case Report: This is case report about an immunosuppressed 68-year-old patient with diabetic macular edema, who developed acute retinal necrosis 74 days after Ozurdex® implantation. He suffers from chronic myeloid leukemia and takes the cytostatic imatinib 400 mg once per day. Urgent pars plana vitrectomy (PPV) with silicone oil instillation was performed and antiherpetic drugs were initiated intravenously. Serological examination confirmed an active infection of cytomegalovirus etiology (CMV).
Conclusion: Acute retinal necrosis is a rare necrotizing retinitis. Corticosteroids administered intravitreally reduce the local immune response, which may cause a primary infection or reactivation of a latent viral infection.
Keywords:
chronic myeloid leukemia – imatinib – diabetic macular edema – dexamethasone – acute retinal necrosis – imunosupression
Zdroje
1. Zafar A, Aslanides I, Selimis V et al. Uneventful Anterior Migration of Intravitreal Ozurdex implant in a patient with iris-sutured intraocular lens and descement stripping automated endothelial keratoplasty. Case Rep Ophthalmol. 2018;9:143-148.
2. Summary of Product Characteristics of Ozurdex® [Internet]. Date of revision: 19.6.2018. [cited 2021 Dec 1]. Avaliable from: https:// www.ema.europa.eu/en/documents/product-information/ozurdex- epar-product-information_sk.pdf
3. Kapoor K, Colchao J. Safety of consecutive same-day bilateral intravitreal dexamethasone implant (Ozurdex). Retin Cases Brief Rep. 2020;14:200-202.
4. Olson D, Parhiz A, Wirthlin R. Reactivation of Latent Toxoplasmosis Following Dexamethasone Implant Injection. Ophthalmic Surg Lasers Imaging Retina. 2016;47:1050-1052.
5. Goel N. Acute bacterial endophthalmitis following intravitreal dexamethasone implant: A case report and review of literature. Saudi Journal of Ophthalmology. 2017;31:51-54.
6. Lee S, Jung JW, Park SW, Lee JE, Byon IS. Retinal injury following intravitreal injection of a dexamethasone implant in a vitrectomized eye. Int J Ophthalmol. 2017;10:1019-1020.
7. Celik N, Khoramnia R, Auffarth G, Sel S, Mayer S. Complications of dexamethasone implants: risk factors, prevention and clinical management. Int J Ophthalmol. 2020;13:1613-1620.
8. Kucukevcilioglu M, Eren M, Yolcu U, Sobaci G. Acute retinal necrosis following intravitreal dexamethasone (Ozurdex) implant. Arq Bras Oftalmol. 2015;78:118-119.
9. Dogra M, Rohilla V, Dogra M, Singh R. Macular cytomegalovirus retinitis following dexamethasone intravitreal implant combined with phacoemulsification. Indian J Ophthalmol. 2018;66:1361-1363.
10. Zhang Z, Liu X, Jiang T. Acute retinal necrosis following dexamethasone intravitreal implant (Ozurdex®) administration in an immunocompetent adult with a history of HSV encephalitis: a case report. BMC Ophthalmology. 2020;20:1-7.
11. Hillenkamp J, Nolle B, Bruns C, Rautenberg P, Fickenscher H, Roider J. Acute retinal necrosis: clinical features, early vitrectomy, and outcomes. Ophthalmology. 2009;116:1971-1975.
12. Majumder P, Biswas J, Ambreen A et al. Intravitreal dexamethasone implant for the treatment of cystoid macular oedema associated with acute retinal necrosis. J Ophthal inflamm. 2016;6:1-4.
13. Chang S, Weissgold D, Singer J, Sobrin L. Acute retinal necrosis following intraocular Triamcinolone acetonide injection. Retin Cases Brief Rep. 2010;4:306-308.
14. Han J, Ahn J, Park KH, Woo SJ. Presumed necrotizing viral retinitis after intravitreal triamcinole injection: case report. Korean J Ophthalmol. 2011;25:451-454.
15. Shah AM, Oster SF, Freeman WR. Viral retinitis after intravitreal triamcinolone injection in patients with predisposing medical comorbidities. Am J Ophthalmol. 2010;149:433-440.
Štítky
OphthalmologyČlánok vyšiel v časopise
Czech and Slovak Ophthalmology
2022 Číslo 3
Najčítanejšie v tomto čísle
- INTRAVENOUS THROMBOLYTIC THERAPY FOR ACUTE NONARTERITIC CENTRAL RETINAL ARTERY OCCLUSION. A REVIEW
- EVALUATION OF THE CORNEAL STROMAL DEMARCATION LINE AFTER THE ACCELERATED CORNEAL CROSS-LINKING USING ANTERIOR SEGMENT OCT
- TOPIRAMATE-INDUCED BILATERAL ANGLE-CLOSURE GLAUCOMA. A CASE REPORT
- ACUTE RETINAL NECROSIS AFTER INTRAVITREAL DEXAMETHASONE IMPLANT. A CASE REPORT